Brokers Set Expectations for FULC FY2029 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.95) per share for the year. HC Wainwright currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Price Performance

Shares of FULC stock opened at $3.32 on Thursday. The business’s fifty day moving average price is $4.13 and its 200 day moving average price is $4.62. Fulcrum Therapeutics has a 1-year low of $2.86 and a 1-year high of $13.70. The firm has a market capitalization of $179.08 million, a PE ratio of -10.71 and a beta of 2.03.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Institutional Trading of Fulcrum Therapeutics

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in Fulcrum Therapeutics by 2.3% in the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock valued at $667,000 after purchasing an additional 3,126 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after purchasing an additional 4,701 shares during the last quarter. American Century Companies Inc. grew its holdings in Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock valued at $567,000 after purchasing an additional 6,770 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Fulcrum Therapeutics in the fourth quarter valued at $38,000. Finally, Wells Fargo & Company MN grew its holdings in Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock valued at $161,000 after purchasing an additional 8,761 shares during the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.